20 October 2023
Ropes & Gray Represents Summa Equity in its Sale of Protein Biomarker Platform Olink to Thermo Fisher Scientific
Advising firms
Deal team
8 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Suni Sreepada Lead | Ropes & Gray | Partner | mergers & acquisition | Not stated |
| Renata Ferrari | Ropes & Gray | Partner | executive compensation & employee benefits | Not stated |
| Kyle Higley | Ropes & Gray | Partner | executive compensation & employee benefits | Not stated |
| Ben Rogers | Ropes & Gray | Partner | tax | Not stated |
| Chris Capuzzi | Ropes & Gray | Partner | capital markets & governance | Not stated |
| Marc Rotter | Ropes & Gray | Counsel | Not stated | Not stated |
| Yoni Levy | Ropes & Gray | Partner | asset management | Not stated |
| Dan Sotsky | Ropes & Gray | Associate | mergers & acquisitions | Not stated |
Stated terms
- Stated value
- USD 3.10bn ($3.1 billion)
- What the figure measures
- Total transaction value
- Client
- Summa Equity ABSell-side
- Counterparties
- Thermo Fisher Scientific Inc (Buy-side)
Olink Holding AB (Target)